0000000000175533

AUTHOR

Francesco Dotta

showing 5 related works from this author

Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular …

2012

Abstract Background and aims Metformin is the first-line therapy in type 2 diabetes. In patients inadequately controlled with metformin, the addition of a sulfonylurea or pioglitazone are equally plausible options to improve glycemic control. However, these drugs have profound differences in their mechanism of action, side effects, and impact on cardiovascular risk factors. A formal comparison of these two therapies in terms of cardiovascular morbidity and mortality is lacking. The TOSCA.IT study was designed to explore the effects of adding pioglitazone or a sulfonylurea on cardiovascular events in type 2 diabetic patients inadequately controlled with metformin. Methods Multicentre, random…

Blood GlucoseMaleBIO/12 - BIOCHIMICA CLINICA E BIOLOGIA MOLECOLARE CLINICAEndocrinology Diabetes and Metabolismpioglitazone sulfonylurea type 2 diabetes metformin cardiovascular eventsMedicine (miscellaneous)Type 2 diabetesSettore MED/13 - EndocrinologiaBody Mass Indexlaw.inventionRandomized controlled trialRisk FactorslawSurveys and QuestionnairesCardiovascular DiseasepioglitazonepiogllitazoneStrokeDiabetes Therapy PioglitazoneNutrition and DieteticsDiabetesThiazolidinedionecardiovascular events; pioglitazone; Type 2 Diabetes Mellitus; sulphonylureasType 2 diabetesMiddle AgedMetforminSulfonylurea CompoundTreatment OutcomeTolerabilitysulphonylureasCardiovascular DiseasesDrug Therapy CombinationFemaletype 2 diabetesCardiology and Cardiovascular MedicineHumanmedicine.drugmedicine.medical_specialtyEndpoint Determinationsulfonylureacardiovascualr eventSudden deathFollow-Up Studiecardiovascular eventsInternal medicineDiabetes mellitusmedicineHumansHypoglycemic Agentssulfonylureasinterventio trialtype 2 diabetes; cardiovascular events; pioglitazone; sulfonylureas; randomized controlled trialAgedHypoglycemic AgentQuestionnairebusiness.industryRisk Factormedicine.diseaseSurgeryType 2 Diabetes MellitusSulfonylurea CompoundsDiabetes Mellitus Type 2randomized controlled trialQuality of LifeThiazolidinedionesTherapybusinessmetforminPioglitazoneFollow-Up Studies
researchProduct

Dietary intake and major food sources of polyphenols in people with type 2 diabetes: The TOSCA.IT Study

2018

Purpose: Proper evaluation of polyphenols intake at the population level is a necessary step in order to establish possible associations with health outcomes. Available data are limited, and so far no study has been performed in people with diabetes. The aim of this work was to document the intake of polyphenols and their major food sources in a cohort of people with type 2 diabetes and in socio-demographic subgroups. Methods: We studied 2573 men and women aged 50–75 years. Among others, anthropometry was measured by standard protocol and dietary habits were investigated by food frequency questionnaire (EPIC). The intake of polyphenols was evaluated using US Department of Agriculture and Ph…

0301 basic medicineMaleAge BMI Diabetes Diet Flavonoids Food groups Geographical area Intake Phenolic acids Polyphenols TOSCA.IT study Aged Antioxidants Beverages Cinnamates Cohort Studies Cross-Sectional Studies Databases Factual Diabetes Mellitus Type 2 Female Flavonoids Fruit Glycosides Humans Italy Male Middle Aged Nutritive Value Phenols Polyphenols Diet Diabetic Diet Healthy Patient ComplianceSettore MED/09 - Medicina InternaDatabases FactualCross-sectional studyMedicine (miscellaneous)Type 2 diabetesDiabeteAntioxidantsSettore MED/13 - EndocrinologiaFood groupCohort Studies0302 clinical medicineDiet DiabeticMedicineFood scienceGlycosidesAge; BMI; Diabetes; Diet; Flavonoids; Food groups; Geographical area; Intake; Phenolic acids; Polyphenols; TOSCA.IT study; Medicine (miscellaneous); Nutrition and DieteticsNutrition and DieteticsPhenolic acidDiabetesfood and beveragesMiddle AgedPolyphenols Flavonoids Phenolic acids Diabetes Food groups Diet Age BMI Geographical area Intake TOSCA.IT studyItalyToscaAgeBMIDiabetesDietFlavonoidsFood groupsGeographical areaIntakePhenolic acidsPolyphenolsTOSCA.IT studyCohortIntakeFemaleDiet HealthyNutritive ValueCohort studyPolyphenolPhenolic acids030209 endocrinology & metabolismBeverages03 medical and health sciencesBMIAgePhenolsDiabetes mellitusHumansAgedFlavonoidsGeographical area030109 nutrition & dieteticsbusiness.industryTOSCA.IT studyPolyphenolsAnthropometrymedicine.diseaseFood groupDietToscaCross-Sectional StudiesDiabetes Mellitus Type 2Food groupsPolyphenolCinnamatesAge; BMI; Diabetes; Diet; Flavonoids; Food groups; Geographical area; Intake; Phenolic acids; Polyphenols; TOSCA.IT studyFruitFlavonoidPatient Compliancebusiness
researchProduct

Unexpected subcellular distribution of a specific isoform of the Coxsackie and adenovirus receptor, CAR-SIV, in human pancreatic beta cells

2018

Aims/hypothesis: The Coxsackie and adenovirus receptor (CAR) is a transmembrane cell-adhesion protein that serves as an entry receptor for enteroviruses and may be essential for their ability to infect cells. Since enteroviral infection of beta cells has been implicated as a factor that could contribute to the development of type 1 diabetes, it is often assumed that CAR is displayed on the surface of human beta cells. However, CAR exists as multiple isoforms and it is not known whether all isoforms subserve similar physiological functions. In the present study, we have determined the profile of CAR isoforms present in human beta cells and monitored the subcellular localisation of the princi…

0301 basic medicineMaleviruksetEndocrinology Diabetes and MetabolismInsulin-Secreting CellsProtein IsoformsReceptorChildProinsulinEnterovirusMicroscopy ConfocalChemistryNuclear ProteinsImmunogold labellingMiddle AgedFlow CytometryImmunohistochemistryTransmembrane protein3. Good healthCell biologyEndocrinologieenteroviruksetMédecine interneProtein interacting with C-kinase 1 (PICK1)medicine.anatomical_structureChild PreschoolCoxsackievirus BFemalePancreasPICK1Gene isoformBeta cells; Coxsackie and adenovirus receptor; Coxsackievirus B; Enterovirus; Insulin granule; Pancreas; Protein interacting with C-kinase 1 (PICK1)AdultCoxsackie and Adenovirus Receptor-Like Membrane ProteinAdolescentImmunoprecipitationBlotting WesterninsuliiniArticle03 medical and health sciencesYoung AdultMétabolismeInternal MedicinemedicineHumansImmunoprecipitationPancreasCoxsackie and adenovirus receptorInsulin granuleDiabétologieBeta cellshaima030104 developmental biologyDiabetes Mellitus Type 1Carrier ProteinsDiabetologia
researchProduct

40(th) EASD Annual Meeting of the European Association for the Study of Diabetes : Munich, Germany, 5-9 September 2004

2004

0303 health sciencesmedicine.medical_specialtybusiness.industryEASDEndocrinology Diabetes and MetabolismHuman physiologymedicine.disease03 medical and health sciences0302 clinical medicineDiabetes mellitusFamily medicineInternal MedicineMedicinebusiness030217 neurology & neurosurgery030304 developmental biology
researchProduct

Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-…

2017

Background Dapagliflozin is a sodium-glucose cotransporter-2 inhibitor approved for the treatment of type 2 diabetes. We aimed to assess the efficacy and safety of dapagliflozin as an add-on to adjustable insulin in patients with inadequately controlled type 1 diabetes. Methods DEPICT-1 was a double-blind, randomised, parallel-controlled, three-arm, phase 3, multicentre study done at 143 sites in 17 countries. Eligible patients were aged 18–75 years and had inadequately controlled type 1 diabetes (HbA1c between ≥7·7% and ≤11·0% [≥61·0 mmol/mol and ≤97·0 mmol/mol]) and had been prescribed insulin for at least 12 months before enrolment. After an 8 week lead-in period to optimise diabetes man…

MaleGlycated Hemoglobin AEndocrinology Diabetes and MetabolismType 2 diabetes030204 cardiovascular system & hematologySettore MED/13 - Endocrinologialaw.inventionchemistry.chemical_compound0302 clinical medicineEndocrinologydiabetes dapaglifozinGlucosidesRandomized controlled triallawInsulin03.02. Klinikai orvostanDapagliflozinMiddle AgedDiabetes and MetabolismTreatment OutcomeCombinationDrug Therapy CombinationFemaleType 1Adultmedicine.medical_specialtyDiabetic ketoacidosis030209 endocrinology & metabolismPlacebo03 medical and health sciencesDrug TherapyDiabetes managementDiabetes mellitusInternal medicineDiabetes MellitusInternal MedicinemedicineHumansHypoglycemic AgentsBenzhydryl CompoundsAdult; Benzhydryl Compounds; Body Weight; Diabetes Mellitus Type 1; Drug Therapy Combination; Female; Glucosides; Glycated Hemoglobin A; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Middle Aged; Treatment OutcomeAdult; Benzhydryl Compounds; Body Weight; Diabetes Mellitus Type 1; Drug Therapy Combination; Female; Glucosides; Glycated Hemoglobin A; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Middle Aged; Treatment Outcome; Internal Medicine; Endocrinology Diabetes and Metabolism; EndocrinologyGlycated HemoglobinType 1 diabetesbusiness.industryBody Weightmedicine.diseaseHypoglycemiaSurgeryDiabetes Mellitus Type 1chemistrybusinessThe Lancet Diabetes & Endocrinology
researchProduct